Purpose Raised circulating levels of the potent vasoconstrictor endothelin-l (ET-l ) have been demonstrated in diabetes and pregnancy induced hypertension. Pregnant women with diabetic retinopathy are known to be at a higher risk of developing pregnancy-induced hypertension than those without retinopathy.
Vascular endothelial cells produce a potent and long-lasting vasoconstrictor called endothelin-1 (ET-1). ET-1 is constitutively expressed by the vascular endothelium and is thought to play a key role in the autoregulation of blood flow. 1 Diabetes is a condition characterised by abnormalities in blood flow? Elevated levels of ET -1 have been demonstrated in diabetes, suggesting that this in some way may be related to these changes in blood flow? Pregnancy results in major changes in blood flow to all the major organs. There is a state of generalised vasodilation of the vascular system4 with a resultant increase in blood flow, cardiac output and circulating plasma blood. s It would seem that diabetic women, in particular those with compromised vasculature, may have difficulties in making these adjustments during pregnancy and thus may run the risk of developing complications as the pregnancy progresses. It has been shown that women with diabetes, in particular those with diabetic retinopathy, show an increased risk of developing pregnancy induced hypertension, 6 .7 a disease characterised by endothelial dysfunction and also known to be associated with elevated ET-1 levels.s
To date there have been no studies examining plasma levels of ET -1 in diabetic pregnancy. Thus the aim of the present study was to measure circulating levels of ET-1 in diabetic and normal pregnancy. The presence or absence of diabetic retinopathy was used as an attempt to identify those who had pre-existing vasculopathy. Therefore, the levels of ET-1 were compared in those with and without diabetic retinopathy.
Subjects and methods

Subjects
Thirteen women with insulin-dependent diabetes mellitus (type 1) diagnosed prior to pregnancy were recruited from the combined antenatal/metabolic clinic at the Royal Maternity Hospital, Belfast. Eight normal women whose pregnancy was being managed in the same unit were recruited to form the control group. Informed consent was obtained from each volunteer prior to enrolment into the study. Ethics approval had been obtained from the local ethics committee. Patients were recruited at presentation in the first trimester of pregnancy and followed throughout the gestation period and post-partum. All women with diabetes had a full ophthalmic assessment at this time including retinal photography. Photographs were graded using a modification of the Airlie House Classification 9 in a masked fashion, and progression of retinopathy was defined as a change by one or more steps to a higher level. Glycaemic control was assessed using measurements of glycosylated haemoglobin (HbA le ) (DCA 2000 HbA l e Detection Kit, Bayer Diagnostics, France; normal range 4.6-7%). Blood pressure was measured using a Hawksley random zero sphygmomanometer. Baseline characteristics including age, duration of diabetes and blood pressure are summarised in Table 1 .
Radioimmunoassay for ET-l
The protocol for radioimmunoassay (RIA) has been described previously. lO Briefly 10 ml of whole blood was centrifuged (3K for 10 min) and the clear supernatant collected. For each millilitre of plasma a volume of 1.6 ml of ethanol was added. After vigorous agitation the samples were placed in a centrifuge and spun at 2K for 30 min. The supernatant was carefully decanted from the mixture and placed in a glass container. Each container was then placed in a tissue dryer and ethanol extracts were then dried under a stream of nitrogen for 24 h and stored at -20°C until used. A commercial RIA kit (Peninsula Laboratories, UK) containing 1 2 s I-endothelin-1 (specific activity 1.5 mCi) was used for detection of ET-1. The primary antibody consisted of rabbit antiserum specific for human ET-1. Goat anti-rabbit antiserum was used as the secondary antibody. The antibody to ET-1 showed 7% cross-reactivity with ET-2, 7% with ET-3 and 17% with human Big ET-1. All assays were performed in duplicate. The recovery rate of ET-1 by RIA of plasma samples spiked with 500 pg of ET-1 was 88%. The IC s o value for the ET-1 assay was 116 pg/ml and the sensitivity of the assay was 3.75 pg/ml. The inter-and intra-assay coefficients of variation were 17% and 12% respectively.
Statistical analysis
Results of plasma immunoreactive ET-1 (ir-ET-1) were expressed as medians with a minimum and maximum range. The Mann-Whitney U-test, the Wilcoxon rank sum test and Spearman's correlation coefficients were used to test for statistical significance. The changes in ET -1 levels between each trimester were examined using Friedman analysis. A probability of <0.05 was considered significant.
Results
The concentrations of peptide in each plasma sample were expressed as picograms per millilitre of blood (pg/ml). The results are shown in Tables 1 and 2 . Table 1 shows the levels of ir-ET-1 present in the plasma in each trimester in women with diabetes (n = 13) versus controls (n = 8). There were no differences in baseline characteristics between the two groups with respect to age, or systolic and diastolic blood pressure (p = 0.7, P = 0.2 and p = 0.3). In women without diabetes there was a non-significant increase in ir-ET-1 during pregnancy (p = 0.1). Women with diabetes had significantly greater levels of ir-ET-1 throughout pregnancy compared with their normal counterparts (p = 0.0001, P = 0.0001 and p = 0.0005 in the first, second and third trimesters, respectively). On comparison of ir-ET-1 plasma levels in diabetic women with retinopathy (n = 7) versus those without retinopathy (n = 6), no significant difference was detected. There was a trend for lower ir-ET -1 levels in early pregnancy in those with retinopathy but this did not reach statistical significance (p = 0.07).
Three patients with diabetes showed progression of retinopathy during pregnancy, which was clearly seen on grading fundus photographs. When patients were categorised according to whether or not retinopathy progressed, the plasma levels of ir-ET -1 in early pregnancy were significantly lower in diabetics who subsequently showed worsening of retinopathy compared with those who showed no change in retinopathy status (p = 0.03). This difference was also apparent in mid-trimester (p = 0.04), but there was no significant difference in late pregnancy and in the post partum period.
Discussion
There have been several studies measuring plasma levels of ET-1 in pregnancy. One such study has shown a gradual increase in ET -1 from first to third trimester in normal pregnancyY Other studies have measured ET-1 in pregnancy-induced hypertension; these have shown elevated levels of ET-1 in the third trimester. 8 • 11 To our knowledge this is the first study to look at ET -1 in diabetic pregnancy. The results of this study are in broad agreement with previous studies in that ET-1 has been shown gradually to increase during normal pregnancy. The results show, however, that the women with diabetes had significantly increased ET-1 levels throughout pregnancy compared with normal. The reasons for this are unclear. Diabetes is itself associated with elevated ET -1 levels, 3 the reasons for which are unclear. In vitro studies have shown that insulin increases the synthesis of ET -1 by vascular endothelial cellsY In pregnancy, insulin requirements are elevated. 13 It could be that the increased exogenously administered insulin may upregulate ET-1 synthesis during pregnancy. Alternatively, increased ET -1 levels in diabetes may indicate endothelial cell dysfunctionY It is possible that the increase in ET-1 levels puts pregnant women with diabetes at increased risk of developing pregnancy-induced hypertension. Only 3 women developed pregnancy-induced hypertension in this study although levels of ir-ET-1 in these patients were not significantly different from those in the other women with diabetes.
Pregnancy is associated with an increased risk of progression of diabetic retinopathy. IS The results of this study showed that there was no difference in ir-ET-1 levels between those with and those without retinopathy, although there was a trend for those with retinopathy to have lower ir-ET-1 levels. There may be several reasons for a lack of association between diabetic retinopathy and ir-ET-1Ievels. Firstly, the numbers of individuals in this study are small. Secondly, the presence or absence of retinopathy may not be a good indicator of endothelial dysfunction. Changes in retinal blood flow have been demonstrated before the development of the clinical features of diabetic retinopathy. 1 6 Finally, the method of grading retinopathy used in this study may not have been sensitive enough to detect minor changes. A more accurate method may have been to measure retinal blood flow throughout pregnancy and relate this to ET -1 levels. Previous studies have shown that an increase in retinal blood flow in pregnancy is associated with progression of diabetic retinopathy. 17 Only 3 patients in this study showed progression of retinopathy. These patients showed lower levels of ir-ET-1 in early pregnancy compared with those who did not (p = 0.03). However, in such a small number of patients it is difficult to determine the real impact of this finding. Larger prospective studies measuring ET -1 levels in early pregnancy are required to test the significance of this result. If an association between ET-1 levels and progression of retinopathy is demonstrated a simple predictive test based on an ET-1 assay could be useful to physicians and obstetricians who supervise pregnancies in women with diabetes, as this could alert them to the possibilities of complications such as progression of retinopathy.
In summary, this study has shown that ir-ET-1Ievels are raised during pregnancy in women with diabetes. This may help to explain why women with diabetes have an increased risk of developing complications of pregnancy such as pregnancy-induced hypertension and progression of diabetic retinopathy. Larger studies are required to test the significance of these results.
